1V-LSD

1V-LSD, also known as 1-valeryl-LSD or by the nickname Valerie, is a psychedelic drug of the lysergamide family related to lysergic acid diethylamide. It is an analogue of LSD and is thought to act as a prodrug of LSD.
1V-LSD has been sold online until an amendment to the German NpSG was enforced in 2022 which controls 1P-LSD and now 1cP-LSD, 1V-LSD and several other lysergamides.

Use and effects

1V-LSD has been sold in the form of blotter containing 150μg per tab. Its effects are said to be comparable to 100 to 120μg 1P-LSD or 1cP-LSD, but with a longer duration. On the other hand, other sources report that 1V-LSD has a shorter duration than LSD of 6 to 8hours.

Interactions

Pharmacology

Pharmacodynamics

As demonstrated with other N-acylated derivatives of LSD, 1V-LSD is believed to serve as a prodrug for LSD but may also act directly as a weak partial agonist at the serotonin 5-HT_2A receptor.
A head-twitch response assay in mice found that 1V-LSD has a similar potency to 1P-LSD and 1cP-LSD, with behavioral effects also closely resembling these structural analogs.

Chemistry

Synthesis

1V-LSD is the condensation product of valeric acid and LSD, where the valeroyl group is substituted on the NH position of the indole moiety.

Detection

is used to identify the presence of an indole moiety; the chemical backbone of the lysergamide and ergoline molecules. However, as with other N-acylated lysergamides, 1V-LSD reacts very slowly to Ehrlich reagent and may not give reliable results if the reagent isn't fresh.

Analogues

Related compounds include 1B-LSD, 1cP-LSD, 1D-LSD, 1P-LSD, and AL-LAD, among others.

Society and culture

Sweden

Since 2 March 2022, 1V-LSD has been under investigation in Sweden and may therefore soon become controlled.

United States

1V-LSD is not an explicitly controlled substance in the United States. However, it could be considered a controlled substance under the Federal Analogue Act if intended for human consumption.